Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AFN 1252

Known as: AFN-1252, AFN1252 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Background: AFN-1252 is a novel inhibitor of FabI, which is essential in Staphylococcus spp. This study evaluated the safety… Expand
Is this relevant?
2015
2015
This open-label noncontrolled, phase II multicenter trial was designed to evaluate the safety, tolerability, and efficacy of 200… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2015
2015
AIMS AFN-1252 is a novel inhibitor of FabI, an essential enzyme in Staphylococcus spp. This study was undertaken to assess the… Expand
  • figure 1
  • figure 2
Is this relevant?
2013
2013
OBJECTIVES To investigate the absorption, distribution, metabolism and excretion of AFN-1252, a novel inhibitor of the essential… Expand
Is this relevant?
2013
2013
Abstract AFN-1252 is a novel inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252… Expand
Is this relevant?
2013
2013
AFN-1252 is a potent antibiotic against Staphylococcus aureus that targets the enoyl-acyl carrier protein reductase (FabI). A… Expand
  • table 1
Is this relevant?
2013
2013
Abstract AFN-1252, a new antimicrobial agent, specifically and potently inhibits fatty acid synthesis in Staphylococcus aureus… Expand
Is this relevant?
2013
2013
This study examines the alteration in Staphylococcus aureus gene expression following treatment with the type 2 fatty acid… Expand
Is this relevant?
2012
2012
The mechanism of action of AFN-1252, a selective inhibitor of Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI… Expand
Is this relevant?
2009
2009
AFN-1252, a potent inhibitor of enoyl-acyl carrier protein reductase (FabI), inhibited all clinical isolates of Staphylococcus… Expand
Is this relevant?